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Abstract
Background: Online adaptive radiotherapy is intended to prevent plan degradation caused by inter-fractional
tumor volume and shape changes, but time limitations make online re-planning challenging. The aim of this study
was to compare the quality of online-adapted plans to their respective reference treatment plans.
Methods: Fifty-two patients treated on a ViewRay MRIdian Linac were included in this retrospective study. In total
238 online-adapted plans were analyzed, which were optimized with either changing of the segment weights (n =
85) or full re-optimization (n = 153). Five different treatment sites were evaluated: prostate, abdomen, liver, lung and
pelvis. Dosimetric parameters of gross tumor volume (GTV), planning target volume (PTV), 2 cm ring around the PTV
and organs at risk (OARs) were considered. The Wilcoxon signed-rank test was used to assess differences between
online-adapted and reference treatment plans, p < 0.05 was considered significant.
Results: The average duration of the online adaptation, consisting of contour editing, plan optimization and quality
assurance (QA), was 24 ± 6min. The GTV was slightly larger (average ± SD: 1.9% ± 9.0%) in the adapted plans than
in the reference plans (p < 0.001). GTV-D95% exhibited no significant changes when considering all plans, but GTV-
D2% increased by 0.40% ± 1.5% on average (p < 0.001). There was a very small yet significant decrease in GTV-
coverage for the abdomen plans. The ring Dmean increased on average by 1.0% ± 3.6% considering all plans (p <
0.001). There was a significant reduction of the dose to the rectum of 4.7% ± 16% on average (p < 0.001) for
prostate plans.
Conclusions: Dosimetric quality of online-adapted plans was comparable to reference treatment plans and OAR
dose was either comparable or decreased, depending on treatment site. However, dose spillage was slightly
increased.
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Background
Developments in image-guided radiotherapy (IGRT) contrib-
ute to more precise and accurate radiation treatment deliv-
ery. Imaging patients immediately prior to or during
treatment improves patient set-up and makes it possible to
perform real-time corrections, which prevent plan degrada-
tions caused by tumor progression and anatomical changes
[1]. These online adaptations allow for reduced safety mar-
gins in the planning phase, increased tumor dose, and better
sparing of organs at risk (OARs) [2]. This could eventually
lead to improved tumor control and reduced toxicity.
Modern linear accelerators (linacs) are often equipped
with a cone-beam computed tomography (CBCT) system,
which allows for two-, three and four-dimensional patient
positioning verification. Although CBCT images are able
to detect anatomical changes and trigger adaptive re-
planning, IGRT is limited by the CBCT’s increased noise
level and low soft-tissue contrast, especially in the abdo-
men and pelvic regions, when compared to conventional
CT. Moreover, CBCT acquisitions deposit additional dose
outside the treatment volume.
The combination of magnetic resonance imaging (MRI)
and linac (MR-linac) makes it possible to use imaging with
superior soft tissue contrast during the course of radiation
treatment and in the treatment position, without adding
imaging dose to the patient [3–5]. These properties make
an MR-linac suitable for MR-guided adaptive radiotherapy
(MRgART), which includes MR-guided radiation delivery
as well as online treatment plan adaptations to match daily
anatomy [6]. Previous studies have shown that it was pos-
sible to achieve a plan quality with an MR-linac that was
comparable to that of conventional linacs [7–9]. MR-linacs
are currently installed in multiple centers worldwide, and
several studies have reported on their experience of using
MR-linacs for online-adaptive radiotherapy [10–13]. The
use of MRgART was previously described for rectum, pros-
tate, abdomen (pancreas and liver), lung, and the pelvic re-
gion [7, 11, 12, 14–20]. These studies showed the feasibility
of MRgART and the possibility to reduce planning target
volume (PTV) margins and limit OAR doses.
In the MR-guided online-adaptive workflow, daily MR
images are acquired while the patient is in the treatment
position and registered to the reference MRI scan.
Thereafter, contours are edited, and the treatment plan
is recalculated on the new MRI and re-optimized. Previ-
ous studies have reported a duration of around 50 min
for the online-adaptive workflow [11, 12, 14, 15]. Since
the patients are in the treatment position during this en-
tire procedure, the aim is to perform efficient and fast
online adaptations to improve patient comfort and to
avoid anatomical changes during this lap of time (i.e.
intra-fractional changes). However, despite the limited
time available for adapting the treatment plan according
to the daily anatomy, it is important that the plan quality
remains high. Therefore, in order to detect potential
plan quality degradations for patients receiving daily
adapted treatments, the aim of this study was to retro-
spectively compare the (dosimetric) plan quality of all
online-adapted treatment plans to their respective refer-
ence treatment plans, which were considered optimal.
Materials and methods
A ViewRay MRIdian Linac (Viewray, Inc., Oakwood Vil-
lage, Ohio, USA) has been operational at the University
Hospital of Zürich since April 2019. The MRIdian is a
0.345 T MRI integrated with a 6 MV flattening filter-free
(FFF) linac [21, 22]. The machine is able to deliver a
dose rate of 600 cGy/min at 90 cm source-to-axis dis-
tance (SAD). It is equipped with a double-stacked
double-focused multi-leaf collimator (MLC) with a leaf
width of 8.3 mm at the isocentric plane, corresponding
to an effective leaf width of 4.15 mm. The MRIdian has
an integrated adaptive treatment planning system (TPS)
that allows for online adaptation of treatment plans
based on an MRI acquired in treatment position.
Patients
All patients that received daily adaptive treatments on the
MRIdian between April 2019 and November 2019, in total
52, were included in this retrospective analysis. This in-
cludes patients with the tumor sites lung, prostate, liver,
pelvis, pancreas, kidney, adrenal gland, or abdomen (other).
The tumor sites pancreas, kidney, adrenal gland, and abdo-
men (other) were analyzed together as ‘abdomen’. Details
about the patients and treatments included in the study are
presented in Table 1.
Treatment planning
For treatment planning purposes, an MRI scan was per-
formed with the MR-linac in treatment position. Add-
itionally, a CT scan in the same position and with coils
was acquired, usually within a 1 h timeframe, in order to
obtain the electron density information required for dose
calculation. All MRI scans were acquired using a bal-
anced steady-state free precession (bSSFP) sequence,
resulting in T2/T1-weighted contrast. The in-plane reso-
lution was 1.5 × 1.5 mm, whereas the slice thickness was
set to either 1.5 mm for tumors in the pelvic region
(scan duration ~ 90 s) or 3 mm for moving tumors (scan
duration ~ 23 s), since these patients are imaged in
breath-hold. The CT and MRI scans were co-registered,
after which relevant structures were contoured on the
MRI. During contouring, any functions used for creating
targets or planning help structures were saved as ‘rules’;
for example, gross tumor volume (GTV) to PTV expan-
sion, or a 2 cm ring around the PTV to control dose
conformity. During adaptive re-planning these rules
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Table 1 Overview of the patients included in this study. “n=” Indicates the number of patients. FX = fractions; GTV = Gross Tumor















Planned Delivered Full Weight




Pancreas 3 5*6.6 Gy (n =
2)
5*8.0 Gy (n =
1)




Bowel (n = 1)
Stomach (n = 1)
Kidney 2a 5*6.0 Gy (n =
1)
5*8.0 Gy (n =
1)
SBRT (n = 2) 9 9 5 4 14.1 [2.1–
26.0]
37.5 [8.4–66.6] Bowel (n = 1)
Adrenal
gland
5 5*6.0 Gy (n =
3)
5*7.0 Gy (n =
2)






Bowel (n = 3)
Abdomen,
other
8 2*5.0 Gy (n =
1)
3*3.0 Gy (n =
1)
5*6.0 Gy (n =
2)
5*6.6 Gy (n =
1)
5*7.0 Gy (n =
1)
5*8.0 Gy (n =
1)




SBRT (n = 7)




Bowel (n = 3)
Stomach (n = 3)














Rectum (n = 8)
Bladder (n = 8)
Prostate IMRT 5 3*2.0 Gy (n =
3)
4*2.0 Gy (n =
1)




19 19 5 13 1.8 [0.77–3.3] 11.3 [5.7–12.1] Rectum (n = 5)
Bladder (n = 5)




5*8.0 Gy (n =
1)
5*9.0 Gy (n =
3)
8*6.0 Gy (n =
2)








Liver 9 38 38 31
(82%)
7 (18%)
Liver SBRT 5a 5*6.0 Gy (n =
1)
5*9.0 Gy (n =
3)
6*5.0 Gy (n =




Bowel (n = 1)
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allow the creation of help structures to be performed ac-
curately within seconds.
All patients were treated with step-and-shoot intensity-
modulated radiotherapy (IMRT) composed of 9–11
beams, which were often arranged as a ‘pseudo-arc’. The
beams were generally spaced evenly around the patient for
a central target, whereas the beams are mostly limited to
one side of the patient for lateralized targets, depending
on exact tumor location. Small changes were made to
these beam arrangements to avoid treating through couch
edges, or the arms of the patient. For patients with
breathing-induced tumor motion the PTV margin around
the GTV was set to 7–10mm in the longitudinal direction
and 6–10mm in the other directions. For tumors in the
pelvic region, a margin between 3 and 5mm was used.
Margins were defined according to institutional guide-
lines, which were based on experience from the conven-
tional linac margins, but slightly adapted for the MR-linac
considering increased intra-fractional errors.
The majority of patients were treated using a stereotac-
tic body radiotherapy (SBRT) dose prescription. For the
SBRT cases, dose was prescribed to cover 95–99% of the
PTV (V100% ≥ 95%). The prescription isodose line was ei-
ther 65% or 80% of the maximum dose, depending on size
of the tumor, proximity of OARs and previous delivered
dose (if any). For the 65% isodose prescription, dose max-
imum (D0.1cc) was allowed between 152 and 156%, and
the minimum dose to 95% of the GTV (D95%) was 135%.
For the 80% isodose prescription, D0.1cc was between 123
and 127% and GTV-D95% ≥ 113%. A few patients received
a second series boost treatment on the MR-linac, for
which a low fraction dose (≤3 Gy) and homogeneous dose
prescription was used (referred to as ‘non-SBRT’). For
these cases, dose was normalized such that 95% of the
PTV received at least 95% of the prescribed dose (PTV-
V95% ≥ 95%), and the mean of the PTV (Dmean) corre-
sponded to 100% of the prescribed dose. Risk-adapted
fractionation schemes were used, depending on previous
treatments, proximity of OARs, and location of the tumor.
OAR constraints are provided in Table 2. Dose calculation
was done with a Monte Carlo algorithm that takes into ac-
count the magnetic field, and a grid size of 2mm for
SBRT and 3mm for non-SBRT.
MR-guided online-adaptive workflow
Prior to each radiotherapy fraction, a new MRI scan was
acquired to capture the anatomy of the day. In order to
transfer the segmentations, this MRI scan was matched
to the reference MRI using deformable registration. In
the first month the MRI was operational, mostly a previ-
ously online-adapted MRI instead of the reference MRI
was used. But, since we observed that this could cause
an accumulation of changes, the standard became to use
the reference MRI to transfer the segmentations. The
target volume and OAR structures, as well as electron
density information were transferred to the new MRI
scan. Additionally, inaccuracies in parts of the registra-
tions were overwritten with densities of water, air, lung
and bone according to the information of the MRI of
the day. A radiation oncologist edited all contours on
each slice containing the PTV + 2 cm that required adap-
tations, including the GTV if necessary, after which the
predefined rules were applied. Subsequently, the dose
was recalculated on the new MRI scan. This predicted
plan was then optimized by means of an automatic
optimization of the weights of the static MLC field seg-
ments (i.e. weight optimization). Plans were rated ac-
ceptable if all OAR constraints were fulfilled while PTV
and GTV coverage were as high as possible, allowing for
suboptimal coverage while maintaining OAR sparing: for
all cases considered in this study, the OARs were higher
prioritized than the target. A full new optimization was
performed, if this plan did not meet the acceptance cri-
teria. If necessary, the priorities of the objectives were
changed in order to reduce the OAR dose or to improve
the target coverage. The online-adapted treatment plan
Table 1 Overview of the patients included in this study. “n=” Indicates the number of patients. FX = fractions; GTV = Gross Tumor















Planned Delivered Full Weight
1)










Pelvis 5c 5*6.5 Gy (n =
1)
5*7.0 Gy (n =
4)




4.3 [0.32–5.4] 12.7 [2.5–19.3] Bowel (n = 2)
aOne patient had two lesions: kidney and liver
bOne patient had two lung lesions
cOne patient had two pelvis lesions
dPatient continued treatment on conventional linac
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was final once both physician and physicist approved the
plan, considering the OAR constraints (Table 2). Online
quality assurance (QA) consists of a gamma analysis be-
tween the TPS dose calculation and an independent
Monte-Carlo (MC) dose calculation, and a verification of
path length, plan complexity, integral dose and a point-
dose calculation using a simple Clarkson algorithm.
The treatment workflow is summarized in Fig. 1.
Plan evaluation
The GTV and PTV volumes of the contours in the
online-adapted treatment plans were compared with the
reference treatment plans. Furthermore, a subgroup ana-
lysis was performed to assess whether differences be-
tween online-adapted plans and references plans were
larger for online-adapted plans that were adapted from a
previously online-adapted plan or from the reference
plan.
Besides volumes, the following dose-volume histogram
(DVH) parameters were evaluated for both GTV and
PTV: mean dose (Dmean), dose to 95% of the volume
(D95%), dose to 98% of the volume (D98%), and dose to
2% of the volume (D2%). Additionally, the Dmean and










































Fig. 1 Workflow of treatment using MR-guided online-adaptive radiotherapy on the MRIdian linac
Table 2 OAR constraints
Structure Parameter SBRT - 3 fractions SBRT - 5 fractions SBRT - 8 fractions SBRT - 10 fractions
Tolerance [Gy] Tolerance [Gy] Tolerance [Gy] Tolerance [Gy]
BrachialPlexus D1.0cc [Gy] ≤ 24.00 ≤ 30.00 ≤ 36.00 ≤ 40.00
BronchialTree D1.0cc [Gy] ≤ 32.00 ≤ 40.00 ≤ 50.00 ≤ 54.00
Esophagus D1.0cc [Gy] ≤ 27.00 ≤ 36.00 ≤ 43.00 ≤ 47.00
Heart D1.0cc [Gy] ≤ 36.00 ≤ 45.00 ≤ 55.00 ≤ 60.00
SpinalCord_PRV D1.0cc [Gy] ≤ 19.00 ≤ 23.80 ≤ 32.00 ≤ 35.00
CaudaEquina D1.0cc [Gy] ≤ 22.00 ≤ 27.00 ≤ 33.00 ≤ 36.00
Trachea D1.0cc [Gy] ≤ 32.00 ≤ 40.00 ≤ 50.00 ≤ 54.00
Stomach D1.0cc [Gy] ≤ 21.00 ≤ 26.00 ≤ 31.00 ≤ 33.00
Duodenum D1.0cc [Gy] ≤ 21.00 ≤ 26.00 ≤ 31.00 ≤ 33.00
Bowel D1.0cc [Gy] ≤ 21.00 ≤ 26.00 ≤ 31.00 ≤ 33.00
Rectum D1.0cc [Gy] ≤ 38.00
Bladder D1.0cc [Gy] ≤ 40.00
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the PTV were evaluated, to assess dose conformity and
spillage. The dose to 1.0 cc (D1.0cc) of the organ in closest
proximity with the 2 cm ring was evaluated. For abdomen,
liver, and pelvis patients this was either stomach, duodenum
or bowel. For prostate patients, the D1.0cc in the rectum as
well as in the bladder was evaluated. All described dose pa-
rameters were extracted from both, the reference treatment
plans and the online-adapted treatment plans, and com-
pared. The number of treatment plans that required either
the weight or full optimization strategy was also evaluated.
In addition, the differences in dose parameters between both
optimization strategies were assessed. Besides a plan-wise
comparison, the average values for all online-adapted plans
were calculated per patient, in order to be able to identify pa-
tients for which all adapted plans had superior or inferior
quality compared to the reference plans.
To be clear, all analysis in this study compared the
online-adapted treatment plans to the reference treat-
ment plans, which were made prior to treatment and
were considered optimal plans.
Besides the dose parameters, the average total time the
patients were on the table, as well as the average adapta-
tion time, was calculated for those patients for which this
information was recorded. The adaptation time consists of
the time required to edit the contours, optimize the treat-
ment plan and online QA, responding to the ‘online adap-
tation’ steps in the workflow shown in Fig. 1.
Statistics
Wilcoxon signed-rank test was used to evaluate the differ-
ences between individual dose statistics of the online-
adapted plans and the reference treatment plans, adopting
the null hypothesis that for each metric there are no differ-
ences between the two plans. The test was performed using
the function wilcox.test of the stats package in R (version
3.5.0). P-values below 0.05 were considered significant.
Results
At the time this study was conducted, 87 patients were
treated on the MRIdian at our center since the installa-
tion. In total, 52 patients received daily adaptations and
were included in the current analysis. These patients re-
ceived a total of 55 treatment courses and 247 treatment
fractions. For 51/55 treatment courses, the treatment
time was recorded at least once during the treatment
course. The time was not recorded for two non-SBRT
liver patients, one lung patient and one adrenal gland
patient. Additionally, for one lung patient the adaptation
time was not recorded. The mean ± SD of the average
total time the patient (n = 51) was on the table was
65 ± 9min. The mean ± SD of the average adaptation
time per patient (n = 50) was 24 ± 6min. For the refer-
ence treatment plans there was no time pressure, and a
planner typically makes two treatment plans per day.
For three patients, a new reference treatment plan was
created during the course of treatment: for one patient
the predefined rules were done incorrectly and the plan
had to be redone, for one patient the plan was undeliver-
able since the patient could not be positioned in the re-
quired lateral position, and the third patient had
problems with holding breath so the beam-on time had
to be reduced. Out of all delivered fractions (n = 247),
for nine fractions the online-adapted plan was not deliv-
ered, due to the adaptive QA failing. Therefore, in total
238 online-adapted plans were analyzed in this study.
85/238 plans were optimized using weight optimization,
whereas for the remaining 153 plans a full optimization
was performed. For 37 out of 238 online-adapted plans,
a previous online-adapted plan was used to recalculate
the dose on the new MRI, instead of the reference plan.
Sixteen out of 37 originated from the first month the
MRIdian was operational.
The volume change of the GTV with respect to the
reference treatment plans are shown as percentages in
Fig. 2, whereas the results for PTV are shown in Figure
S1 of [Additional file 1]. For 67/238 (28%) adapted plans,
the GTV was equal to the reference treatment plan.
Thirty-six of those required a full optimization. For 84%
of the adapted plans, the GTV change was ≤1 cm3. The
GTV and PTV in the adapted treatment plans changed
by 1.9 and 2.2% on average, which corresponds to a me-
dian [range] of 0.0 cm3 [− 5.6–12.0] and 0.1 cm3 [− 9.9–
23.7], respectively. For 89/238 adapted plans, the GTV
increased on average more than 2%. For this group, the
majority of plans (67/89, 75.3%) were optimized using
full optimization. The GTV changed by less than 2% for
the other 149/238 adapted plans, and 86/149 (57.7%) of
these plans were optimized using full optimization.
For the 37 plans for which a previous online-adapted
plan was used for adaptation, the change in GTV-
volume was (median [range]) 0.1 cm3 [− 1.1–12.0],
whereas this was 0.0 cm3 [− 5.6–9.7] for the other 201
plans for which the reference plan was used.
Dose statistics for both GTV, PTV and the 2 cm ring
around the PTV, are shown in Table 3. All values are
displayed in percentage differences relative to the refer-
ence treatment plans. The difference in dose parameters
for the full and weighted optimized plans is presented in
Figure S2 of [Additional file 1].
Figure 3 shows the results (D1.0cc) for the OARs. The
last column of Table 1 indicates the OARs that were
considered for abdomen, liver, pelvis, and prostate. Note
that not for all patients a serial OAR was present close
to the tumor.
The differences between the average dose parameters
of all online-adapted treatment plans per patient and the
reference treatment plans are shown in Figure S3 and S4
of [Additional file 1].
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Discussion
In MRgART, treatment plans are adapted to account for
inter-fractional changes in patient anatomy using MRI
scans that are acquired while the patient is in treatment
position. The time for the adaptation process should prefer-
ably be as short as possible, while maintaining high treat-
ment plan quality. Therefore, in this study, the (dosimetric)
plan quality of online-adapted treatment plans was com-
pared to that of the reference treatment plans, which were
considered optimal for the purpose of this study.
A significant increase in volume from the reference to
the online-adapted plan was observed in both GTV and
PTV, which could potentially be explained by radiother-
apy induced edema or tumor swelling. A change in GTV
or PTV volume might also be due to time pressure dur-
ing adaptation, although it is yet unknown if time pres-
sure could have caused a systematic increase.
A previous study reported an average increase in GTV
and PTV of 0.5 cm3 and 0.8 cm3, respectively, for 25 per-
ipherally located lung tumors [15]. This study mentioned
potential uncertainty in contours caused by inter-
observer variability and lack of experience in MR-based
contouring of small lung tumors. We observed smaller
changes: absolute mean decrease of 0.07 cm3 in GTV
and 0.6 cm3 increase in PTV, due to the initialization of
the local rule to not adapt the GTV in the lungs (lung
tumors in this study were peripherally located). Palacios
et al. reported a large spread in GTV changes for the ab-
dominal region, which were caused by rotations and de-
formations, potentially due to tumor progression [23]. In
that study, PTV volume was largely reduced (15%) in
two patients to achieve further OAR sparing.
The subgroup analysis does not show a clear difference
in GTV-volume changes between online-adapted plans
based on previously online-adapted plans (n = 37) or the
reference plans (n = 201). But, this change of workflow
within the study timeframe is a limitation. Note that for
all analyses in this study, the online-adapted plans were
compared to the reference plans.
The target coverage was comparable between the
online-adapted plans and the reference plans. The me-
dian change in both GTV and PTV dose parameters
stayed within 1%. The same is the case for the GTV-
Dmean, which is considered an important parameter for
Fig. 2 Boxplots indicating the relative volume difference in GTV of the adapted plans compared to the respective reference treatment plans.
Diamonds indicate the mean. Dashed lines indicate 0% and dotted lines indicate ±2% differences. Asterisks indicate significance: p-value< 0.05 (*),
p-value< 0.01 (**) and p-value< 0.001 (***)
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Table 3 Relative differences (%) in dosimetric parameters of the GTV, PTV and 2 cm ring around the PTV (‘Ring’), between the
adapted plans and the reference plans. All mean changes larger than 1% are marked in bold. GTV: Gross Tumor Volume, PTV:
Planning Target Volume, SD: Standard Deviation
ALL Abdomen Liver Liver (non-
SBRT)
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Mean ± SD −0.24 ± 3.6 −0.55 ± 5.2 −0.56 ± 5.8 − 1.1 ± 1.7 0.08 ± 1.2 0.10 ± 0.44 − 0.05 ± 0.55 0.37 ± 0.96














0.18[− 2.4–5.9] −0.16[− 2.0–1.4] 0.16[− 2.6–
2.2]
Mean ± SD −0.25 ± 5.4 −0.18 ± 5.7 0.37 ± 8.9 −5.4 ± 10.8 −0.57 ± 3.6 0.74 ± 1.9 −0.15 ± 0.77 0.40 ± 1.17












Mean ± SD 0.14 ± 3.1 0.37 ± 1.4 −1.3 ± 8.7 0.15 ± 0.30 0.41 ± 1.5 0.62 ± 0.91 − 0.10 ± 0.67 −0.11 ± 1.5
P-value < 0.0001 0.04 0.21 0.17 0.15 < 0.0001 0.80 0.71
Ring
Dmean
Median 0.80[−15.8– 1.0[−7.2–8.4] 1.6[− 4.5–8.1] −0.28[− 4.7–2.7] 0.80[−4.2–7.8] − 0.17[− 15.8– 0.00[− 10.0–2.7] 1.5[− 1.9–
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local tumor control. Small changes compared to the ref-
erence plan were observed in the online-adapted plans;
meaning that it was possible to maintain a high effective
dose in the online-adaptive workflow [24, 25]. Neverthe-
less, some changes in PTV- and GTV dose parameters
may seem larger than expected in treatments on the
conventional linac. Because of the possibility to perform
daily adaptations, the dose prescribed to the PTV is lar-
ger than treatment on the conventional linac, whereas
the same OAR constraints were used. In each adaption,
the aim was to obtain the best coverage of PTV and
GTV without exceeding the tolerance limits for OARs.
Overall, the largest range of changes in dose parameters
was observed for abdominal patients. For this group,
OAR constraints were often violated because one of the
organs was in close proximity to the PTV. Also, there is
a lot of movements of close organs caused by digestion.
Therefore, often the PTV had to be compromised, and
Table 3 Relative differences (%) in dosimetric parameters of the GTV, PTV and 2 cm ring around the PTV (‘Ring’), between the
adapted plans and the reference plans. All mean changes larger than 1% are marked in bold. GTV: Gross Tumor Volume, PTV:
Planning Target Volume, SD: Standard Deviation (Continued)
ALL Abdomen Liver Liver (non-
SBRT)
Lung Prostate Prostate (non-
SBRT)
Pelvis
[range] 13.1] 6.8] 13.1]
Mean ± SD 1.0 ± 3.6 1.4 ± 3.2 1.6 ± 3.4 −0.14 ± 2.2 1.8 ± 2.9 −0.89 ± 5.3 −0.51 ± 2.7 2.5 ± 3.4




0.56 [−10.5–6.8] 0.72[− 4.3–6.0] 0.21[− 2.0–6.8] 0.00[−1.7–0.86] 1.6[−3.5–4.9] − 0.10[− 10.5–
3.0]
0.34[− 1.1–1.9] 1.3[− 0.24–
5.8]
Mean ± SD 0.64 ± 2.1 0.71 ± 1.5 0.90 ± 2.1 − 0.07 ± 0.79 1.3 ± 2.0 −0.70 ± 3.3 0.35 ± 0.78 1.6 ± 1.4
P-value < 0.0001 < 0.0001 0.11 0.84 0.002 0.86 0.11 < 0.0001
Fig. 3 Boxplot indicating relative change of OAR D1.0cc of adapted plans with respect to reference treatment plans. For abdomen, liver and pelvis,
either stomach, bowel or duodenum was evaluated. For prostate, both rectum and bladder were evaluated. Diamonds indicate the mean.
Dashed lines indicate 0% and dotted lines indicate ±2% differences. Asterisks indicate significance: p-value< 0.05 (*), p-value< 0.01 (**) and
p-value< 0.001 (***)
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most plans required full optimization. The amount of
overlap between the OAR and PTV, as well as how
much the compromise on the PTV-D95% is, depends on
the PTV margin.
In case of overlapping organs, help structures (e.g.
GTV_PH and PTV_PH) might have been created that are
cropped away from the OAR, which were then used for
treatment planning to ensure meeting the OAR dose tol-
erances. This is according to the concept of simultaneous
integrated protection [26]. For patients with varying over-
lap between OARs and PTV, this can lead to large changes
in the PTV or GTV coverage between the reference plans
and daily-adapted plans. For instance, the outliers in the
abdomen patients can be attributed to one patient with a
kidney tumor. The stomach overlapped with the GTV and
PTV in the reference plan, so GTV_PH and PTV_PH
were used. In two fractions, the stomach did no longer
overlap with the target and thus the PTV-D98% increased
by 25% in both fractions, the GTV-D95% increased by 29
and 31%, and the GTV-D98% increased by 41 and 45%.
But since GTV_PH and PTV_PH were used to optimize
the treatment plans, the dose parameters in these struc-
tures remained stable (within 2%), indicating a robust be-
havior of the optimizer. Similarly, the average significant
decrease in PTV-D98% for the liver cases was mainly
caused by one patient for which the stomach overlapped
more with the PTV in two online-adapted plans than in
the reference plan, causing decreases in the PTV coverage
with respect to the reference plan of more than 25%. In
general for the liver (non-SBRT) patients, who all had
large, diffuse tumors, also the largest GTV and PTV vol-
ume changes were observed. These large anatomical
changes (e.g. changes in GTV volume) make it more diffi-
cult to compare the treatment plan quality of online-
adapted plans with respect to reference treatment plans.
Dose spillage (e.g. dose in the 2 cm ring) was slightly
increased for all plans. This might be caused by the lim-
ited time that is available for optimizing the plans. Sig-
nificant dose spillage increase was observed for both
optimization strategies. For some patients an OAR was
often overlapping or in direct proximity to the PTV, so
daily adaptations of the contours and full optimization
were required. This was the case for a pelvic patient, for
which a 13.1% increase in ring Dmean was observed. In
general, OAR dose (D1.0cc) was comparable between the
online-adapted plans and the reference plans, and
slightly decreased for the rectum. A limitation of this
study is that OAR-Dmean could not be assess to further
evaluate OAR dose, since optimization is only performed
in the MRI image-slices containing the 2 cm ring.
The treatment time was not recorded for all patients
included in this study, which is a limitation of this retro-
spective study. Using the available data, patients were
found to be on the treatment table on average for 65
min, with an average adaptation time of 24 min. Adap-
tive treatment time could be reduced by shortening the
time required for contour adaptations, which could be
achieved by improved deformable registrations, or auto-
matic segmentation using artificial intelligence [27]. Fur-
ther reduction in appointment time could be achieved by
making better-informed decisions about the time spent on
adapting and optimizing the treatment plan. Previous
studies have shown that for different tumor sites that the
majority of fractions the optimized plan was improved
compared to the predicted plan, but that online adaption
might not always be beneficial [12, 14, 15, 17, 18, 23, 28].
Our study did not investigate this aspect, and neither were
the improvements of a full optimization over a weight
optimization studied. The optimization strategy is cur-
rently subject to high inter-observer variability, which is a
limitation of this study. Further studies are required to in-
vestigate the benefits of a full optimization; to provide
guidelines for the choice of either the predicted, weighted
optimized or fully optimized plan, which could potentially
reduce time on the treatment table for some patients. The
current study only shows that for small changes in GTV
(< 2%), a smaller fraction of treatment plans was opti-
mized with full optimization, indicating that the amount
of GTV volume changes might be a useful indicator for
the best suitable optimization approach, considering the
trade-off between treatment time and treatment plan
quality [28]. In the future, automated planning could pos-
sibly contribute to the reduction of treatment time, while
improving overall plan quality and reducing inter-planner
variability [29].
Conclusions
This study demonstrates the feasibility of MR-guided
online-adaptive radiotherapy, and shows a comparable
dosimetric plan quality in online-adapted treatment
plans to those achieved in the reference treatment plan.
The results were different for each treatment site, indi-
cating that online treatment plan evaluation should have
site-specific protocols.
Supplementary information




bSSFP: Balanced steady-state free precession; CBCT: Cone-beam computed
tomography; CT: Computed tomography; DVH: Dose-volume histogram;
FFF: Flattening filter-free; GTV: Gross tumor volume; IGRT: Image-guided
radiotherapy; IMRT: Intensity-modulated radiotherapy; Linac: Linear
accelerator; MLC: Multi-leaf collimator; MRgART: Magnetic resonance guided
adaptive radiotherapy; MRI: Magnetic resonance imaging; OAR: Organ at risk;
PTV: Planning target volume; SAD: Source-to-axis distance; SBRT: Stereotactic
body radiotherapy; SD: Standard deviation; TPS: Treatment planning system




Each author participated in either the acquisition of the data, curation of the
data, conducting analyses, interpreting the results, writing or editing the
manuscript. All authors reviewed the results and approved the final version
of the manuscript.
Funding
Research was supported by a Grant of the Baugarten Foundation Zurich
(KW/MR 2817) and by the SNF R’Equip program (grant 326030_177080 / 1).
There was no further involvement of the funding bodies in the design of the
study and collection, analysis, and interpretation of data and in writing the
manuscript.
Availability of data and materials
All data generated or analyzed during the current study are available from
the corresponding author on reasonable request.
Ethics approval and consent to participate
For this study anonymized patient data was used. According to our local




The authors declare that they have no competing interests.
Received: 4 May 2020 Accepted: 12 August 2020
References
1. Lamb J, Cao M, Kishan A, Agazaryan N, Thomas DH, Shaverdian N, et al.
Online adaptive radiation therapy: implementation of a new process of
care. Cureus. 2017;9:e1618.
2. Wu QJ, Li T, Wu Q, Yin FF. Adaptive radiation therapy: technical
components and clinical applications. Cancer J. 2011;17:182–9.
3. Pollard JM, Wen Z, Sadagopan R, Wang J, Ibbott GS. The future of image-
guided radiotherapy will be MR guided. Br J Radiol. 2017;90:20160667.
4. Pathmanathan AU, van As NJ, Kerkmeijer LGW, Christodouleas J, Lawton
CAF, Vesprini D, et al. Magnetic resonance imaging-guided adaptive
radiation therapy: a “game changer” for prostate treatment? Int J Radiat
Oncol Biol Phys. 2018;100:361–73.
5. Kupelian P, Sonke JJ. Magnetic resonance-guided adaptive radiotherapy: a
solution to the future. Semin Radiat Oncol. 2014;24:227–32.
6. Lagendijk JJ, Raaymakers BW, Van den Berg CA, Moerland MA, Philippens ME,
van Vulpen M. MR guidance in radiotherapy. Phys Med Biol. 2014;59:R349–69.
7. van de Schoot AJAJ, van den Wollenberg W, Carbaat C, de Ruiter P, Nowee
ME, Pos F, et al. Evaluation of plan quality in radiotherapy planning with an
MR-linac. Phys Imaging Radiat Oncol. 2019;10:19–24.
8. Menten MJ, Fast MF, Nill S, Kamerling CP, McDonald F, Oelfke U. Lung
stereotactic body radiotherapy with an MR-linac - quantifying the impact of the
magnetic field and real-time tumor tracking. Radiother Oncol. 2016;119:461–6.
9. Saenz DL, Paliwal BR, Bayouth JE. A dose homogeneity and conformity
evaluation between ViewRay and pinnacle-based linear accelerator IMRT
treatment plans. J Med Phys. 2014;39:64–70.
10. Bertelsen AS, Schytte T, Moller PK, Mahmood F, Riis HL, Gottlieb KL, et al.
First clinical experiences with a high field 1.5 T MR linac. Acta Oncol. 2019;
58:1352–7.
11. Werensteijn-Honingh AM, Kroon PS, Winkel D, Aalbers EM, van Asselen B,
Bol GH, et al. Feasibility of stereotactic radiotherapy using a 1.5T MR-linac:
multi-fraction treatment of pelvic lymph node oligometastases. Radiother
Oncol. 2019;134:50–4.
12. Tetar SU, Bruynzeel AME, Lagerwaard FJ, Slotman BJ, Bohoudi O, Palacios
MA. Clinical implementation of magnetic resonance imaging guided
adaptive radiotherapy for localized prostate cancer. Phys Imaging Radiat
Oncol. 2019;9:69–76.
13. Acharya S, Fischer-Valuck BW, Kashani R, Parikh P, Yang D, Zhao T, et al.
Online magnetic resonance image guided adaptive radiation therapy: first
clinical applications. Int J Radiat Oncol Biol Phys. 2016;94:394–403.
14. Finazzi T, Palacios MA, Spoelstra FOB, Haasbeek CJA, Bruynzeel AME,
Slotman BJ, et al. Role of on-table plan adaptation in MR-guided ablative
radiation therapy for central lung tumors. Int J Radiat Oncol Biol Phys. 2019;
104:933–41.
15. Finazzi T, Palacios MA, Haasbeek CJA, Admiraal MA, Spoelstra FOB, Bruynzeel
AME, et al. Stereotactic MR-guided adaptive radiation therapy for peripheral
lung tumors. Radiother Oncol. 2019;144:46–52.
16. Boldrini L, Cusumano D, Cellini F, Azario L, Mattiucci GC, Valentini V. Online
adaptive magnetic resonance guided radiotherapy for pancreatic cancer:
state of the art, pearls and pitfalls. Radiat Oncol. 2019;14:71.
17. Henke LE, Olsen JR, Contreras JA, Curcuru A, DeWees TA, Green OL, et al.
Stereotactic MR-guided online adaptive radiation therapy (SMART) for
Ultracentral thorax malignancies: results of a phase 1 trial. Adv Radiat Oncol.
2019;4:201–9.
18. Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, et al. Phase
I trial of stereotactic MR-guided online adaptive radiation therapy (SMART)
for the treatment of oligometastatic or unresectable primary malignancies
of the abdomen. Radiother Oncol. 2018;126:519–26.
19. Bohoudi O, Bruynzeel AME, Senan S, Cuijpers JP, Slotman BJ, Lagerwaard FJ,
et al. Fast and robust online adaptive planning in stereotactic MR-guided
adaptive radiation therapy (SMART) for pancreatic cancer. Radiother Oncol.
2017;125:439–44.
20. Alongi F, Rigo M, Figlia V, Cuccia F, Giaj-Levra N, Nicosia L, et al. 1.5 T MR-
guided and daily adapted SBRT for prostate cancer: feasibility, preliminary
clinical tolerability, quality of life and patient-reported outcomes during
treatment. Radiat Oncol. 2020;15:69.
21. Kluter S. Technical design and concept of a 0.35 T MR-Linac. Clin Transl
Radiat Oncol. 2019;18:98–101.
22. Mutic S, Dempsey JF. The ViewRay system: magnetic resonance-guided and
controlled radiotherapy. Semin Radiat Oncol. 2014;24:196–9.
23. Palacios MA, Bohoudi O, Bruynzeel AME, van Sorsen de Koste JR, Cobussen
P, Slotman BJ, et al. Role of daily plan adaptation in MR-guided stereotactic
ablative radiation therapy for adrenal metastases. Int J Radiat Oncol Biol
Phys. 2018;102:426–33.
24. Kestin L, Grills I, Guckenberger M, Belderbos J, Hope AJ, Werner-Wasik M,
et al. Dose-response relationship with clinical outcome for lung stereotactic
body radiotherapy (SBRT) delivered via online image guidance. Radiother
Oncol. 2014;110:499–504.
25. Klement RJ, Sonke JJ, Allgauer M, Andratschke N, Appold S, Belderbos J,
et al. Correlating dose variables with local tumor control in stereotactic
body radiotherapy for early stage non-small cell lung cancer: a modelling
study on 1500 individual treatments. Int J Radiat Oncol Biol Phys. 2020;
107(3):579–86.
26. Brunner TB, Nestle U, Adebahr S, Gkika E, Wiehle R, Baltas D, et al.
Simultaneous integrated protection. Strahlenther Onkol. 2016;192:886–94.
27. Simon A, Nassef M, Rigaud B, Cazoulat G, Castelli J, Lafond C, et al. Roles of
deformable image registration in adaptive RT: from contour propagation to
dose monitoring. Conf Proc IEEE Eng Med Biol Soc. 2015;2015:5215–8.
28. Bohoudi O, Bruynzeel AME, Meijerink MR, Senan S, Slotman BJ, Palacios MA,
et al. Identification of patients with locally advanced pancreatic cancer
benefitting from plan adaptation in MR-guided radiation therapy. Radiother
Oncol. 2019;132:16–22.
29. Krayenbuehl J, Zamburlini M, Ghandour S, Pachoud M, Tanadini-Lang S, Tol J,
et al. Planning comparison of five automated treatment planning solutions for
locally advanced head and neck cancer. Radiat Oncol. 2018;13:170.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Timmeren et al. Radiation Oncology          (2020) 15:203 Page 11 of 11
